Story

Barclays Taps Safran and Melrose as Top European Aero-Engine Stocks

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20261 min read
Barclays Taps Safran and Melrose as Top European Aero-Engine Stocks
Text size
Background

Barclays has named Safran and Melrose as its top investment opportunities in the European aero-engine sector, highlighting distinct value propositions for each company. In a research note, the investment bank outlined its analysis based on financial performance, market position, and balance sheet strength, designating Safran as a quality compounder and Melrose as a prime growth play.

Safran: A 'Quality Compounder'

Barclays rated Safran (SAF) as its top pick, citing what it sees as the strongest combination of growth, visibility, and resilience in the European aerospace sector. The bank pointed to Safran's leading position in narrowbody engines, its expanding defense franchise, and a proven track record of operational execution as key strengths.

Furthermore, the company's net cash balance sheet supports what Barclays termed a "high-quality compounding story." While acknowledging that Safran trades at a premium to its peers, the analysts believe this is justified. Barclays maintained its Overweight rating and raised its price target on the stock to €390 from a previous €370.

Sample IUX Markets – In-articleAd

Melrose: A High-Growth Opportunity

For investors seeking growth, Barclays identified Melrose (MRO), noting it offers the highest free cash flow growth potential in its coverage universe. According to the bank, Melrose provides the greatest leverage to the ramp-up in original equipment manufacturing and the ongoing recovery in widebody aircraft.

Barclays addressed recent uncertainty surrounding the company's Garden Grove facility, arguing that the market's reaction has been excessive. The analysts noted that Melrose's relative underperformance implies approximately £1.4 billion of market value destruction, significantly above the firm's estimate of the likely ultimate financial impact. Due to its smaller size and complexity, Barclays believes Melrose is less efficiently priced than its peers, presenting an opportunity for investors. The firm reiterated its Overweight rating and £7.10 price target.

Read next

More on Stocks
Back to latest news

LATEST